A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Phase 2 Terminated 613 enrolled AstraZeneca Emerald Clinical Inc. · collab Parexel · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.

Timeline

Start: 2020-10-01
Primary completion: 2022-09-06
Completion: 2022-09-06

Publications

Heerspink HJL, Law G, Psachoulia K, Connolly K, Whatling C, Ericsson H, Knochel J, Lindstedt EL, MacPhee I. Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD. Kidney Int Rep. 2021 Aug 27;6(11):2803-2810. doi: 10.1016/j.ekir.2021.08.018. eCollection 2021 Nov.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atuliflapon	Small molecule	—	Oral
Background	Dapagliflozin	Small molecule	10 mg	Oral

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Summary

Timeline

Publications

Drugs

Indications